more

Allergan plc (AGN)

(Delayed Data from NYSE)

$145.81 USD

+1.56 (1.08%)

Updated May 3, 2019 04:01 PM ET

After-Market: $145.88 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.15%
2	Buy	17.88%
3	Hold	9.47%
4	Sell	5.14%
5	Strong Sell	2.57%
S&P	500	11.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

Industry: NA

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Teva (TEVA) Q4 Earnings Miss,'19 View Weak, Shares Down

by Zacks Equity Research Published on February 14,2019

Teva's (TEVA) fourth-quarter earnings miss estimates while sales marginally beat expectations. Guidance for 2019 is lower than expected.

J&J's (JNJ) Depression Treatment Gets FDA Committee's Nod

by Zacks Equity Research Published on February 13,2019

J&J (JNJ) gets FDA advisory committee's positive recommendation for its investigational nasal spray, Spravato (esketamine) for treatment-resistant depression in adults.

pharmaceuticals

Allergan Stock Falls as FDA OK's Botox Rival for Frown Lines

by Zacks Equity Research Published on February 05,2019

Allergan's (AGN) stock declines almost 4% after FDA approves Evolus' Jeuveau injection to treat frown lines, which can pose strong competition to Botox.

pharmaceuticals

Pharma Stock Roundup: Q4 Earnings, Pipeline Updates at PFE, RHHBY

by Zacks Equity Research Published on February 01,2019

Pfizer (PFE), Allergan (AGN), AbbVie (ABBV) and Novartis (NVS) report Q4 results.

pharmaceuticals

Allergan (AGN) Q4 Earnings Beat Estimates, 2019 View Tepid

by Zacks Equity Research Published on January 29,2019

Allergan (AGN) beats fourth-quarter estimates for earnings and sales with Botox being the primary sales driver. The company provides full-year guidance for 2019.

Allergan (AGN) Q4 Earnings Beat Estimates, 2019 View Tepid

by Zacks Equity Research Published on January 29,2019

Allergan (AGN) beats fourth-quarter estimates for earnings and sales with Botox being the primary sales driver. The company provides full-year guidance for 2019.

Allergan (AGN) Beats Q4 Earnings and Revenue Estimates

by Zacks Equity Research Published on January 29,2019

Allergan (AGN) delivered earnings and revenue surprises of 3.37% and 1.99%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

AGNPositive Net Change

Dr. Reddy's (RDY) to Report Q3 Earnings: What's in Store?

by Zacks Equity Research Published on January 28,2019

Dr. Reddy's has launched few generics which should add to revenues of the company when the company releases its third-quarter fiscal 2019 results.

pharmaceuticals

Allergan Hikes Quarterly Dividend by 2.8% Ahead of Q4 Results

by Zacks Equity Research Published on January 28,2019

Allergan (AGN) approves a cash dividend of 74 cents for 2019, a 2.8% raise from the previous payout of 72 cents.

medical

Drug/Biotech Stock Earnings on Jan 29: PFE, AMGN, BIIB & AGN

by Zacks Equity Research Published on January 28,2019

Four drug/biotech stocks are scheduled to release their fourth-quarter results on Jan 29. Let's take a look at how these companies are poised ahead of their earnings release.

Amgen/Allergan's Rituxan Biosimilar Meets Goal in Phase III

by Zacks Equity Research Published on January 25,2019

Amgen (AMGN) along with partner Allergan reports upbeat top-line data from a phase I/III study on ABP 798, a biosimilar candidate of Roche???s Rituxan. The program achieves the primary endpoint.

biotechs

Can Allergan (AGN) Keep the Earnings Streak Alive in Q4?

by Zacks Equity Research Published on January 24,2019

While Allergan's (AGN) Q4 sales are likely to be driven by new as well as established products like Botox, generic competition for some key products is expected to hurt sales.

pharmaceuticals

Pfizer (PFE) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research Published on January 24,2019

While Pfizer's (PFE) new drugs like Ibrance and Xeljanz are likely to drive Q4 sales, genericization of key drugs and weak sales in the EH segment will hurt the same.

pharmaceuticals

Ironwood Commences Phase I Study on IW-6463 for CNS Disorders

by Zacks Equity Research Published on January 24,2019

Ironwood (IRWD) begins a phase I study on CNS-penetrant soluble guanylate cyclase stimulator, IW-6463, for treating severe CNS disorders.

medical

Ironwood's (IRWD) Linzess Gets Approval in China for IBS-C

by Zacks Equity Research Published on January 16,2019

Ironwood Pharmaceuticals (IRWD) gets approval for Linzess in China for the treatment of adults with IBS-C

pharmaceuticals

Pharma Stock Roundup: Lilly to Buy Loxo for $8B, M&A in Focus at JP Morgan Meet

by Zacks Equity Research Published on January 11,2019

Lilly (LLY) is spending $8 billion to buy small cancer biotech Loxo Oncology. Big Pharma CEOs hint at spur in M&A activity in 2019.

pharmaceuticals

Bull of the Day: Editas Medicine (EDIT)

by Kevin Cook Published on January 08,2019

CRISPR gene editing is going to transform the world and this leader just won key patent battles to capitalize

Ironwood to Get New CEO, Current CEO to Head Latest Spinoff

by Zacks Equity Research Published on January 07,2019

Ironwood Pharma (IRWD) appoints AstraZeneca executive, Mark Mellon, as its new chief executive officer. Peter Hecht, the current CEO, will lead the new spinoff company focusing on rare disease.

pharmaceuticals

Ironwood/Allergan Settle Linzess Patent Litigation With Mylan

by Zacks Equity Research Published on January 03,2019

Ironwood (IRWD) and Allergan announce agreement with Mylan to resolve patent litigation, granting Mylan license to launch a generic version of Linzess in the United States not earlier than Feb 5, 2030.